Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose boosterResearch in context

Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose boosterResearch in context

Summary: Background: SARS-CoV-2 booster vaccination should ideally enhance protection against variants and minimise immune imprinting. This Phase I trial evaluated two vaccines targeting SARS-CoV-2 beta-variant receptor-binding domain (RBD): a recombinant dimeric RBD-human IgG1 Fc-fusion protein, a...

Full description

Bibliographic Details
Main Authors: Terry M. Nolan, Georgia Deliyannis, Maryanne Griffith, Sabine Braat, Lilith F. Allen, Jennifer Audsley, Amy W. Chung, Marcin Ciula, Nicholas A. Gherardin, Michelle L. Giles, Tom P. Gordon, Samantha L. Grimley, Lana Horng, David C. Jackson, Jennifer A. Juno, Katherine Kedzierska, Stephen J. Kent, Sharon R. Lewin, Mason Littlejohn, Hayley A. McQuilten, Francesca L. Mordant, Thi H.O. Nguyen, Vanessa Pac Soo, Briony Price, Damian F.J. Purcell, Pradhipa Ramanathan, Samuel J. Redmond, Steven Rockman, Zheng Ruan, Joseph Sasadeusz, Julie A. Simpson, Kanta Subbarao, Stewart A. Fabb, Thomas J. Payne, Asuka Takanashi, Chee Wah Tan, Joseph Torresi, Jing Jing Wang, Lin-Fa Wang, Hareth Al-Wassiti, Chinn Yi Wong, Sophie Zaloumis, Colin W. Pouton, Dale I. Godfrey
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:EBioMedicine
Subjects:
SARS-CoV-2
Vaccine
Receptor binding domain
Recombinant protein
mRNA
Beta variant
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396423004449

Internet

http://www.sciencedirect.com/science/article/pii/S2352396423004449

Similar Items